Can we target CCR2 to treat osteoarthritis? The trick is in the timing!

C-C motif chemokines, including CCL2, CCL7, and CCL12, affect cells that express the C-C chemokine receptor type 2, CCR2, a seven-transmembrane domain G-protein coupled receptor (GPCR) [1]. Signaling through CCR2 has been implicated in many pathologies, including autoimmune disorders, tumor metastasis, atherosclerosis, stroke, neurodegenerative disorders, and neurological complications of HIV [2]. As a GPCR, CCR2 is eminently druggable and many small-molecule antagonists have been tested in clinical trials for different conditions [2, 3].

Source: Osteoarthritis and Cartilage - February 7, 2017 Category: Rheumatology Authors: Rachel E. Miller, Anne-Marie Malfait Source Type: research